Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

opko health inc. - OPK

OPK

Close Chg Chg %
1.17 -0.01 -0.86%

Open Market

1.16

-0.01 (0.86%)

Volume: 2.17M

Last Updated:

Mar 27, 2026, 2:31 PM EDT

Trade Now

Company Overview: opko health inc. - OPK

OPK Key Data

Open

$1.15

 Day Range

1.12 - 1.18

52 Week Range

1.10 - 1.80

 Market Cap

$888.11M

Shares Outstanding

759.07M

 Public Float

386.68M

Beta

1.50

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.30

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.76M

  

OPK Performance

1 Week
 
 4.46%
 
1 Month
 
 -2.50%
 
3 Months
 
 -9.30%
 
1 Year
 
 -31.18%
 
5 Years
 
 -73.77%
 

OPK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About opko health inc. - OPK

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment manages the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

OPK At a Glance

OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, Florida 33137
Phone 1-305-575-4100 Revenue 606.88M
Industry Medical/Nursing Services Net Income -225,680,000.00
Sector Health Services Employees 2,275
Fiscal Year-end 12 / 2026
View SEC Filings

OPK Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.559
Price to Book Ratio 0.754
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -7.649
Enterprise Value to Sales 1.605
Total Debt to Enterprise Value 0.407

OPK Efficiency

Revenue/Employee 266,760.00
Income Per Employee -99,200.00
Receivables Turnover 4.812
Total Asset Turnover 0.294

OPK Liquidity

Current Ratio 3.967
Quick Ratio 3.518
Cash Ratio 2.516

OPK Profitability

Gross Margin 21.10
Operating Margin -36.084
Pretax Margin -39.771
Net Margin -37.187
Return on Assets -10.923
Return on Equity -17.14
Return on Total Capital -13.556
Return on Invested Capital -12.961

OPK Capital Structure

Total Debt to Total Equity 31.293
Total Debt to Total Capital 23.834
Total Debt to Total Assets 20.538
Long-Term Debt to Equity 29.49
Long-Term Debt to Total Capital 22.461
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Opko Health Inc. - OPK

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.00B 863.50M 713.14M 606.88M
Sales Growth
-43.42% -14.01% -17.41% -14.90%
Cost of Goods Sold (COGS) incl D&A
799.70M 631.40M 577.27M 478.83M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
108.66M 105.30M 98.18M 91.63M
Depreciation
20.87M 19.27M 15.54M 13.74M
Amortization of Intangibles
87.78M 86.03M 82.63M 77.89M
COGS Growth
-35.35% -21.05% -8.57% -17.05%
Gross Income
204.49M 232.09M 135.88M 128.05M
Gross Income Growth
-61.97% +13.50% -41.46% -5.76%
Gross Profit Margin
+20.36% +26.88% +19.05% +21.10%
2022 2023 2024 2025 5-year trend
SG&A Expense
446.56M 390.15M 409.43M 347.04M
Research & Development
73.89M 89.59M 105.21M 124.03M
Other SG&A
372.67M 300.56M 304.22M 223.00M
SGA Growth
-18.17% -12.63% +4.94% -15.24%
Other Operating Expense
- - - 4.06M
-
Unusual Expense
152.52M 277.00K 6.31M 669.00K
EBIT after Unusual Expense
(398.64M) (158.33M) (279.87M) (219.65M)
Non Operating Income/Expense
19.18M (12.48M) 316.98M 86.75M
Non-Operating Interest Income
1.98M 3.98M 8.43M 14.81M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
12.06M 13.51M 47.47M 108.46M
Interest Expense Growth
-36.14% +12.03% +251.44% +128.51%
Gross Interest Expense
12.06M 13.51M 47.47M 108.46M
Interest Capitalized
- - - -
-
Pretax Income
(391.52M) (184.32M) (10.36M) (241.36M)
Pretax Income Growth
-2,691.39% +52.92% +94.38% -2,229.32%
Pretax Margin
-38.99% -21.35% -1.45% -39.77%
Income Tax
(63.50M) 4.44M 42.84M (15.71M)
Income Tax - Current - Domestic
394.00K (459.00K) 24.43M (8.21M)
Income Tax - Current - Foreign
10.51M 4.75M 3.67M 7.50M
Income Tax - Deferred - Domestic
(52.83M) (246.00K) 24.91M (2.90M)
Income Tax - Deferred - Foreign
(21.58M) 392.00K (10.17M) (12.10M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(328.40M) (188.86M) (53.22M) (225.68M)
Minority Interest Expense
- - - -
-
Net Income
(328.40M) (188.86M) (53.22M) (225.68M)
Net Income Growth
-989.49% +42.49% +71.82% -324.02%
Net Margin Growth
-32.70% -21.87% -7.46% -37.19%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(328.40M) (188.86M) (53.22M) (225.68M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(328.40M) (188.86M) (53.22M) (225.68M)
EPS (Basic)
-0.4567 -0.2512 -0.0767 -0.3004
EPS (Basic) Growth
-882.15% +45.00% +69.47% -291.66%
Basic Shares Outstanding
719.06M 751.77M 694.02M 751.13M
EPS (Diluted)
-0.4567 -0.2512 -0.0767 -0.3004
EPS (Diluted) Growth
-882.15% +45.00% +69.47% -291.66%
Diluted Shares Outstanding
719.06M 751.77M 694.02M 751.13M
EBITDA
(137.47M) (52.76M) (175.38M) (127.36M)
EBITDA Growth
-313.94% +61.62% -232.41% +27.38%
EBITDA Margin
-13.69% -6.11% -24.59% -20.99%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 3.558
Number of Ratings 7 Current Quarters Estimate -0.07
FY Report Date 03 / 2026 Current Year's Estimate -0.279
Last Quarter’s Earnings -0.04 Median PE on CY Estimate N/A
Year Ago Earnings -0.30 Next Fiscal Year Estimate -0.25
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 7 6
Mean Estimate -0.07 -0.07 -0.28 -0.25
High Estimates -0.05 -0.05 -0.21 -0.10
Low Estimate -0.09 -0.09 -0.34 -0.33
Coefficient of Variance -18.44 -18.44 -16.11 -36.83

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 5
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Opko Health Inc. - OPK

Date Name Shares Transaction Value
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,386,858 Open market or private purchase of non-derivative security Non-derivative transaction at $1.24 per share 265,839,703.92
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,436,448 Open market or private purchase of non-derivative security Non-derivative transaction at $1.25 per share 268,045,560.00
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,503,083 Open market or private purchase of non-derivative security Non-derivative transaction at $1.26 per share 270,273,884.58
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,549,783 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $1.26 per share 270,332,726.58
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,564,783 Open market or private purchase of non-derivative security Non-derivative transaction at $1.26 per share 270,351,626.58
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,566,555 Open market or private purchase of non-derivative security Non-derivative transaction at $1.27 per share 272,499,524.85
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,779,163 Open market or private purchase of non-derivative security Non-derivative transaction at $1.28 per share 274,917,328.64
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,848,891 Open market or private purchase of non-derivative security Non-derivative transaction at $1.28 per share 275,006,580.48
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,849,319 Open market or private purchase of non-derivative security Non-derivative transaction at $1.28 per share 275,007,128.32
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,932,875 Open market or private purchase of non-derivative security Non-derivative transaction at $1.28 per share 275,114,080.00
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,932,876 Open market or private purchase of non-derivative security Non-derivative transaction at $1.29 per share 277,263,410.04
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,966,448 Open market or private purchase of non-derivative security Non-derivative transaction at $1.29 per share 277,306,717.92

Opko Health Inc. in the News